Modul-Bio Overview

  • Founded
  • 2003
  • Status
  • Private
  • Employees
  • 13
  • Latest Deal Type
  • Accelerator/​Inc
  • Investors
  • 1

Modul-Bio General Information


Developer of software for management of biological samples. The company provides services for the management of biological samples with the implementation of bar-code systems and laboratory information management software ad well as enables sharing of biological samples.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Accelerator/Incubator Backed
Primary Industry
IT Consulting and Outsourcing
Other Industries
Other Software
Primary Office
  • 163, avenue de Luminy - Case 935
  • Parc Scientifique Luminy Biotech 2, cedex 09
  • 13288 Marseille
  • France
+33 04 00 00 00 00
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Modul-Bio Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
1. Accelerator/Incubator 05-May-2014 Completed Generating Revenue
To view Modul-Bio’s complete valuation and funding history, request access »

Modul-Bio Executive Team (2)

Name Title Board Seat Contact Info
Laurent Jacotot Co-Founder, Chief Executive Officer and Director
Philippe Vaglio Ph.D Co-Founder & Scientific Director
To view Modul-Bio’s complete executive team members history, request access »

Modul-Bio Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Modul-Bio Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Grand Luminy Accelerator/Incubator 000 0000 000000 0
To view Modul-Bio’s complete investors history, request access »